
Combining Fludara (fludarabine), Cytoxan (cyclophosphamide), and Rituxan (rituximab) was safer and produced a higher response than pairing Campath (alemtuzumab) with Fludara and Cytoxan in patients under age 65 with advanced B-cell chronic lymphocytic leukemia receiving their first treatment.








